![]() PFE 28 Jul 2022 Estimated | Other | $0.4 Per Share |
![]() PFE 28 Jul 2022 | Other | $0.4 Per Share |
![]() PFE 12 May 2022 | Other | $0.4 Per Share |
![]() PFE 27 Jan 2022 | Other | $0.4 Per Share |
![]() PFE 4 Nov 2021 | Other | $0.39 Per Share |
![]() PFE 29 Jul 2021 | Other | $0.39 Per Share |
29 Apr 2025 (20 Days) Date | | - Cons. EPS | - EPS |
4 Feb 2025 Date | | 0.49 Cons. EPS | 0.63 EPS |
28 Jan 2025 Date | | 0.49 Cons. EPS | - EPS |
29 Oct 2024 Date | | 0.62 Cons. EPS | 1.06 EPS |
30 Jul 2024 Date | | 0.46 Cons. EPS | 0.6 EPS |
![]() PFE 28 Jul 2022 Estimated | Other | $0.4 Per Share |
![]() PFE 28 Jul 2022 | Other | $0.4 Per Share |
![]() PFE 12 May 2022 | Other | $0.4 Per Share |
![]() PFE 27 Jan 2022 | Other | $0.4 Per Share |
![]() PFE 4 Nov 2021 | Other | $0.39 Per Share |
![]() PFE 29 Jul 2021 | Other | $0.39 Per Share |
29 Apr 2025 (20 Days) Date | | - Cons. EPS | - EPS |
4 Feb 2025 Date | | 0.49 Cons. EPS | 0.63 EPS |
28 Jan 2025 Date | | 0.49 Cons. EPS | - EPS |
29 Oct 2024 Date | | 0.62 Cons. EPS | 1.06 EPS |
30 Jul 2024 Date | | 0.46 Cons. EPS | 0.6 EPS |
Drug Manufacturers - General Industry | Healthcare Sector | Dr. Albert Bourla D.V.M., Ph.D. CEO | XSGO Exchange | US7170811035 ISIN |
US Country | 88,000 Employees | 24 Jan 2025 Last Dividend | 17 Nov 2020 Last Split | 13 Aug 2012 IPO Date |
Pfizer Inc. is a global biopharmaceutical company with a rich history dating back to 1849. Based in New York, New York, Pfizer has established itself as a leader in the discovery, development, manufacture, marketing, distribution, and sale of innovative biopharmaceutical products. Serving a wide range of therapeutic areas, Pfizer's portfolio includes medicines and vaccines that address a variety of health concerns, from cardiovascular metabolic conditions and infectious diseases to chronic immune and inflammatory diseases. The company has a significant global footprint, operating across the United States, Europe, and other international markets, catering to wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and more. Through strategic collaboration agreements with entities like Bristol-Myers Squibb Company, Astellas Pharma US, Inc., Merck KGaA, and BioNTech SE, Pfizer continues to lead in the development of medical breakthroughs for unmet medical needs.